miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.

PLoS One · 2014 · PMC4062472 · PMID 24940606

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Performance status and KRAS were also significant factors in the multivariable analysis, although KRAS was borderline significant as a univariate factor (HR = 1.36, CI 95%: 0.94–1.97). miR-345 as a Single miRNA Marker for Clinical Outcome miR-345 was also predictive for PFS, HR by IQR = 1.7, (CI 95%: 1.31–2.2, adjusted Bonferroni P -value = 0.021).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.